<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696696</url>
  </required_header>
  <id_info>
    <org_study_id>NYU 06-882</org_study_id>
    <nct_id>NCT00696696</nct_id>
  </id_info>
  <brief_title>Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase II Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the combination of two targeted therapies,along with chemotherapy treatment
      in the treatment of pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Until very recently, additional therapies in pancreatic cancer have targeted either the
      vascular endothelial growth factor (VEGF) or epidermal growth factor (EGF) pathways, a
      strategy which has shown variable clinical efficacy. This inconsistency is not surprising,
      given the knowledge that tumors have a certain level of signal redundancy which may limit the
      effectiveness of any one single-targeted therapy. The dual blockade of the EGF and VEGF
      pathways takes aim at two of the most active cascades in tumorigenesis. Preliminarily, a
      phase II study done in pancreatic cancer with gemcitabine, bevacizumab and erlotinib or
      cetuximab has shown promising results and will most likely proceed to phase III study for
      definitive efficacy assessment (Kindler et al, 2006).

      In this study, targeted blockade is carried one step further with the inhibition of the
      signaling cascade downstream of receptor tyrosine kinases at the level of raf. Given the fact
      that the majority of pancreatic tumors display constitutive activation of the Ras/Raf/MEK/ERK
      pathway, it is hoped that the addition of sorafenib to gemcitabine and erlotinib will obtain
      a more complete blockade of the signal transduction cascade responsible for pancreatic tumor
      growth and progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>4-month Progression Free Survival (PFS) Rate</measure>
    <time_frame>4 months</time_frame>
    <description>The PFS rate at 4 months is defined as the percentage of patients whose disease is progression free at 4 months from the start of treatment. Disease progression is evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al, 2000). Radiological measurements to determine progression is performed every 2 cycles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 1 year</time_frame>
    <description>The response rate is the percentage of the patients who have a complete response or partial response based on RECIST from the start of the treatment. The response is evaluated every 2 cycles by radiologic methods (e.g., computer tomography (CT)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (mOS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Median overall survival is defined as the time when 50% of the patients are alive from the start of the treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Combination GES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Gemcitabine, Erlotinib, and Sorafenib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.</description>
    <arm_group_label>Combination GES</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.</description>
    <arm_group_label>Combination GES</arm_group_label>
    <other_name>Tarceva</other_name>
    <other_name>OSI-774</other_name>
    <other_name>CP-358</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.</description>
    <arm_group_label>Combination GES</arm_group_label>
    <other_name>Nexavar</other_name>
    <other_name>BAY 43-9006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed pancreatic adenocarcinoma not amenable to
             curative treatment with surgery. Patients with locally advanced disease must have
             disease that extends outside the boundaries of a standard radiation port.

          -  Measurable disease, as defined by Response Evaluation Criteria In Solid Tumors
             (RECIST). This requires at least one lesion that can be accurately measured in at
             least one dimension (longest diameter to be recorded) as &gt;20 mm with conventional
             techniques or as &gt;10 mm with spiral CT scan. Pleural effusions and ascites are not
             considered measurable lesions.

          -  No prior cytotoxic chemotherapy for metastatic disease. Prior adjuvant chemotherapy is
             allowed, however at least 6 months must have elapsed from administration of the last
             dose of chemotherapy or radiotherapy.

          -  No prior therapy with a VEGF, EGFR, or multi-targeted kinase inhibitor.

          -  Age &gt;18 years.

          -  Life expectancy of greater than 3 months.

          -  Eastern Cooperative Oncology Group performance status 0-1.

          -  Normal organ and marrow function as defined below:

               -  White blood cells (WBC) &gt;3,000/µl

               -  Absolute neutrophil count &gt;1,500/µl

               -  Platelets &gt;100,000/µl

               -  Total bilirubin ≤ 2.5 x institutional upper limit of normal (ULN)

               -  Transaminases(SGOT/ SGPT)

                    -  without liver mets ≤ 2.5 x institutional ULN

                    -  with liver mets ≤ 5 x institutional ULN

               -  International Normalized Ratio (INR)

                    -  patients not on warfarin ≤ 1.5

                    -  patients on warfarin ≤ 3

               -  Renal Function: Serum creatinine ≤ 1.5 xULN

               -  Proteinuria: Urine protein &lt;1+, or 24hr urine protein &lt;500 mg

          -  At least 30 days since receiving any investigational drug.

          -  Patients who received prior radiation therapy must have a site of measurable disease
             that is not located within the prior radiation port.

          -  Patients who are on warfarin anticoagulation are allowed to participate as long as
             they fit the following 3 criteria:

               -  They are therapeutic on a stable warfarin dose

               -  Their INR target range is no greater than 3

               -  They are monitored with regular INR testing

          -  Women of childbearing potential must have a negative serum pregnancy test performed
             within 7 days prior to the start of treatment.

          -  Women of childbearing potential and men must agree to use adequate contraception
             (barrier method birth control) prior to study entry and for the duration of study
             participation. Men should use adequate birth control for at least three months after
             the last administration of study drugs.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  No prior treatment with bevacizumab, cetuximab, or erlotinib. Prior gemcitabine in the
             adjuvant setting completed more than six months previously will be allowed.

          -  No other investigational agents.

          -  No central nervous system (CNS) disease, including primary brain tumors, brain
             metastasis, or history of a cerebro-vascular accident (CVA) or transient ischemic
             attack (TIA) within 6 months of starting therapy.

          -  No allergic reactions to compounds similar to erlotinib or sorafenib.

          -  Because an increased risk of bleeding may occur following sorafenib administration, no
             patients will be allowed with a history of bleeding diathesis or coagulopathy. No
             grade &gt; 2 pulmonary hemorrhage or &gt; grade 3 other hemorrhage within 28 days of
             beginning therapy.

          -  No recent invasive procedures defined as follows: Major surgical procedure, open
             biopsy or significant traumatic injury within 28 days prior to Day 1 of therapy

          -  No Patients with clinically significant cardiovascular disease, defined as:

               -  Uncontrolled hypertension

               -  Myocardial infarction &lt; 6 months prior to registration and new onset angina
                  within 3 months (controlled stable angina acceptable)

               -  New York heart association grade II or greater congestive heart failure, serious
                  cardiac arrhythmia requiring medication, unstable angina pectoris

               -  Grade II or greater peripheral vascular disease

          -  No serious or non-healing wound, ulcer, or bone fracture.

          -  No active infection requiring parental antibiotics.

          -  No currently active second malignancy other than non-melanoma skin cancer or carcinoma
             in-situ of the cervix.

          -  If a patient is on full-dose anticoagulants (warfarin or low molecular weight heparins
             are allowed), the following criteria should be met for enrollment: they must have a
             therapeutic INR, no greater than 3, on a stable dose of warfarin.

          -  No use of thrombolytic agents within 1 month of study initiation.

          -  No gastrointestinal tract disease resulting in an inability to take oral medication or
             prior surgical procedures affecting absorption. This may include patients with or
             without requirements for IV alimentation.

          -  No women who are pregnant (positive pregnancy test) or nursing. Fertile men and women
             must agree to use adequate contraceptive measures during study therapy and for at
             least 3 months after the completion of antibody therapy.

          -  Because patients with immune deficiency are at increased risk of lethal infections
             when treated with marrow-suppressive therapy, no HIV-positive patients, including
             those receiving combination anti-retroviral therapy, are allowed on the study.

          -  Any condition that impairs patient's ability to swallow whole pills

          -  Any malabsorption problem
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deirdre Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Desert Regional Medical Center</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kindler HL, K. A. Bylow, H. S. Hochster, G. Friberg, K. Micetich, G. Locker, M. Kozloff, M. Moore, W. Sun, E. E. Vokes, and University Of Chicago Phase II Consortium. A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients with advanced pancreatic cancer: A preliminary analysis. J. Clin. Oncol (Meeting Abstracts) June 2006, vol. 24 no. 18_suppl 4040</citation>
  </reference>
  <reference>
    <citation>Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.</citation>
    <PMID>10655437</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <results_first_submitted>November 18, 2011</results_first_submitted>
  <results_first_submitted_qc>November 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2011</results_first_posted>
  <last_update_submitted>May 31, 2016</last_update_submitted>
  <last_update_submitted_qc>May 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic adenocarcinoma</keyword>
  <keyword>metastatic</keyword>
  <keyword>EGRF inhibitor</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>combined cancer therapy</keyword>
  <keyword>kinase inhibitor</keyword>
  <keyword>VEGF-R inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study enrolled 45 patients from September 2007 to May 2010 at New York University Medical center and affiliated hospital, New York, NY and Desert Regional Medical center, Palm Springs, CA.</recruitment_details>
      <pre_assignment_details>One patient was enrolled but then withdrew consent before treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combination GES</title>
          <description>Combination of Gemcitabine, Erlotinib, and Sorafenib</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26">number of patients off treatment due to progression of disease only</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination GES</title>
          <description>Combination of Gemcitabine, Erlotinib, and Sorafenib</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="9" lower_limit="45" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>4-month Progression Free Survival (PFS) Rate</title>
        <description>The PFS rate at 4 months is defined as the percentage of patients whose disease is progression free at 4 months from the start of treatment. Disease progression is evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al, 2000). Radiological measurements to determine progression is performed every 2 cycles.</description>
        <time_frame>4 months</time_frame>
        <population>Based on the number of patients treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination GES</title>
            <description>Combination of Gemcitabine, Erlotinib, and Sorafenib</description>
          </group>
        </group_list>
        <measure>
          <title>4-month Progression Free Survival (PFS) Rate</title>
          <description>The PFS rate at 4 months is defined as the percentage of patients whose disease is progression free at 4 months from the start of treatment. Disease progression is evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al, 2000). Radiological measurements to determine progression is performed every 2 cycles.</description>
          <population>Based on the number of patients treated.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <description>The response rate is the percentage of the patients who have a complete response or partial response based on RECIST from the start of the treatment. The response is evaluated every 2 cycles by radiologic methods (e.g., computer tomography (CT)).</description>
        <time_frame>up to 1 year</time_frame>
        <population>Based on the number of patients evaluable for response. The evaluable patients were those patients who received any treatment and had first response assessment followed by at least one confirmatory scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination GES</title>
            <description>Combination of Gemcitabine, Erlotinib, and Sorafenib</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>The response rate is the percentage of the patients who have a complete response or partial response based on RECIST from the start of the treatment. The response is evaluated every 2 cycles by radiologic methods (e.g., computer tomography (CT)).</description>
          <population>Based on the number of patients evaluable for response. The evaluable patients were those patients who received any treatment and had first response assessment followed by at least one confirmatory scan.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (mOS)</title>
        <description>Median overall survival is defined as the time when 50% of the patients are alive from the start of the treatment.</description>
        <time_frame>up to 2 years</time_frame>
        <population>Based on the number of patients treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination GES</title>
            <description>Combination of Gemcitabine, Erlotinib, and Sorafenib</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival (mOS)</title>
          <description>Median overall survival is defined as the time when 50% of the patients are alive from the start of the treatment.</description>
          <population>Based on the number of patients treated.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195" lower_limit="144" upper_limit="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 1 year (treatment period plus 30 days after the treatment)</time_frame>
      <desc>All the events were included regardless they were related or not related to the treatment drugs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combination GES</title>
          <description>Combination of Gemcitabine, Erlotinib, and Sorafenib</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac general</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hemorrhage (GI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>constitutional symptoms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>infection with normal Anc or grade 1 or 2 neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>infection with unknown Anc</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>blood/bone marrow-other</sub_title>
                <counts group_id="E1" events="25" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>edema: limb</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hemoglobin</sub_title>
                <counts group_id="E1" events="25" subjects_affected="14" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>leukocytes</sub_title>
                <counts group_id="E1" events="35" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>neutrophils/granulocytes</sub_title>
                <counts group_id="E1" events="18" subjects_affected="6" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>vision-blurred vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="54" subjects_affected="25" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hemorrhage (GI)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hemorrhoid</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>mucositis/stomatitis (functional/symptomatic)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>mucositis/stomatits (clinical exam)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="36" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="21" subjects_affected="11" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>constitutional symptons-other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="36" subjects_affected="21" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>fever (in the absence of neutropenia)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hemorrhage/bleeding-other</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>metabolic/laboratory-other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="42" subjects_affected="21" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>pain-other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>rigors/chills</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>syndromes-other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia (fever of unknown origin without clinically or microbiologically documentation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>infection with normal Anc or grade 1 or 2 neutrophils</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>infection-other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>serum glutamic oxaloacetic transaminase (ALT/SGOT)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>serum glutamic pyruvic transaminase (AST/SGPT)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>bicarbonate, serum-low</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hypernatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>mood alteration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>neuropathy: sensory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hemorrhage (pulmonary/upper respiratory)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hiccoughs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>pulmonary/upper respiratory-other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>voice changes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bruising</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>dermatology/skin-other</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hair loss/alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>nail changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>petechiae/purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>rash/desquamation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="32" subjects_affected="17" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Deirdre Cohen, MD</name_or_title>
      <organization>NYU Cancer Institute</organization>
      <phone>212-731-5656</phone>
      <email>deirdre.cohen@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

